Literature DB >> 18508515

Osteopontin as a target for cancer therapy.

Nicholas I F Johnston1, Vignesh Kumar Gunasekharan, Amod Ravindranath, Ciara O'Connell, Patrick G Johnston, Mohamed K El-Tanani.   

Abstract

Osteopontin (OPN) is a glycophosphoprotein cytokine that has multiple functions. OPN is expressed and secreted by various cells, and has a role in cell adhesion, chemotaxis, prevention of apoptosis, invasion, migration and anchorage-independent growth of tumor cells. Extensive research has demonstrated the pivotal participation of OPN in the regulation of cell signaling which controls neoplastic and malignant transformation. The elevated expression of OPN has been observed in a variety of cancers. OPN has been linked with tumor metastasis and signifies a poor prognosis for the patient. This review details the mechanisms by which OPN facilitates these pathological events. It will also show that gaining an understanding of the mechanism of OPN's action at a cellular level has led to the development of a number of therapeutic strategies against the cytokine. These include inhibiting its expression, antagonizing cell surface receptor activation and blocking downstream cell signaling pathways. In addition to the potential of these therapies, serum levels of OPN could be used as a diagnostic and prognostic marker. The authors propose that with further research and development, osteopontin directed treatment could greatly enhance outcomes for cancer patients.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18508515     DOI: 10.2741/3009

Source DB:  PubMed          Journal:  Front Biosci        ISSN: 1093-4715


  31 in total

1.  Matricellular proteins osteopontin and osteonectin/SPARC in pancreatic carcinoma.

Authors:  Anne M Delany
Journal:  Cancer Biol Ther       Date:  2010-07-01       Impact factor: 4.742

2.  Identification of osteopontin as a novel marker for early hepatocellular carcinoma.

Authors:  Sufen Shang; Amelie Plymoth; Shaokui Ge; Ziding Feng; Hugo R Rosen; Suleeporn Sangrajrang; Pierre Hainaut; Jorge A Marrero; Laura Beretta
Journal:  Hepatology       Date:  2011-12-19       Impact factor: 17.425

3.  Gene expression profiling of paraffin-embedded primary melanoma using the DASL assay identifies increased osteopontin expression as predictive of reduced relapse-free survival.

Authors:  Caroline Conway; Angana Mitra; Rosalyn Jewell; Juliette Randerson-Moor; Samira Lobo; Jérémie Nsengimana; Sara Edward; D Scott Sanders; Martin Cook; Barry Powell; Andy Boon; Faye Elliott; Floor de Kort; Margaret A Knowles; D Timothy Bishop; Julia Newton-Bishop
Journal:  Clin Cancer Res       Date:  2009-11-03       Impact factor: 12.531

4.  Relationship between osteopontin and β-catenin immunohistochemical expression and prognostic parameters of colorectal carcinoma.

Authors:  Nermeen S Youssef; Wesam M Osman
Journal:  Int J Clin Exp Pathol       Date:  2015-02-01

5.  Elevated serum osteopontin levels in chronic hepatitis C virus infection: association with autoimmune rheumatologic manifestations.

Authors:  Iman H Bassyouni; Rasha H Bassyouni; Nermin H Ibrahim; Ahmed F Soliman
Journal:  J Clin Immunol       Date:  2012-06-24       Impact factor: 8.317

6.  Prognostic and predictive values of SPP1, PAI and caveolin-1 in patients with oral squamous cell carcinoma.

Authors:  Cong-Fa Huang; Guang-Tao Yu; Wei-Ming Wang; Bing Liu; Zhi-Jun Sun
Journal:  Int J Clin Exp Pathol       Date:  2014-08-15

Review 7.  Classic and Novel Adipocytokines at the Intersection of Obesity and Cancer: Diagnostic and Therapeutic Strategies.

Authors:  Nikolaos Spyrou; Konstantinos I Avgerinos; Christos S Mantzoros; Maria Dalamaga
Journal:  Curr Obes Rep       Date:  2018-12

8.  Osteopontin splice variant as a potential marker for metastatic disease in pancreatic adenocarcinoma.

Authors:  Ali A Siddiqui; Elizabeth Jones; Darren Andrade; Apeksha Shah; Thomas E Kowalski; David E Loren; Galina Chipitsyna; Hwyda A Arafat
Journal:  J Gastroenterol Hepatol       Date:  2014-06       Impact factor: 4.029

Review 9.  Osteopontin as potential biomarker and therapeutic target in gastric and liver cancers.

Authors:  Dong-Xing Cao; Zhi-Jie Li; Xiao-Ou Jiang; Yick Liang Lum; Ester Khin; Nikki P Lee; Guo-Hao Wu; John M Luk
Journal:  World J Gastroenterol       Date:  2012-08-14       Impact factor: 5.742

10.  Osteopontin splice variants expression is involved on docetaxel resistance in PC3 prostate cancer cells.

Authors:  K D M Nakamura; T M Tilli; J L Wanderley; A Palumbo; R M Mattos; A C Ferreira; C E Klumb; L E Nasciutti; E R Gimba
Journal:  Tumour Biol       Date:  2015-09-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.